HLA-G molecules are ligands for the inhibitory immune receptors, LILRB1 and LILRB2 (also known as ILT2 and ILT4) (131), and are frequently expressed by solid tumors, therefore, anti-HLA-G CAR-NK can both target tumor cells and relieve immunosuppression. Here, LILRB1 is linked to neoplasm.